FibroBiologics, Inc. received notice on February 3, 2026, about potential delisting from Nasdaq due to failing to meet the market value threshold of $35 million set by Nasdaq Listing Rule 5550(b)(2). The company is actively working on a plan to regain compliance, including a possible reverse stock split of 1-for-5 to 1-for-30 shares.